2017
B cells require Type 1 interferon to produce alloantibodies to transfused KEL‐expressing red blood cells in mice
Gibb DR, Liu J, Santhanakrishnan M, Natarajan P, Madrid DJ, Patel S, Eisenbarth SC, Tormey CA, Stowell SR, Iwasaki A, Hendrickson JE. B cells require Type 1 interferon to produce alloantibodies to transfused KEL‐expressing red blood cells in mice. Transfusion 2017, 57: 2595-2608. PMID: 28836263, PMCID: PMC5745367, DOI: 10.1111/trf.14288.Peer-Reviewed Original ResearchConceptsBone marrow chimeric miceHuman KEL glycoproteinType 1 interferonB cellsMean fluorescence intensityChimeric miceRed blood cell antigensBlood cell antigensGerminal center B cellsWT B cellsRBC alloimmunizationIgG alloantibodiesAlloimmune responseB cell differentiationRed blood cellsTransfusion protocolControl miceInflammatory stateWT miceAutoimmune pathologyIgG productionIFNAR1 expressionPlasma cellsAntiviral immunityInflammatory stimuli
2010
In vitro and in vivo evaluation of a whole blood platelet‐sparing leukoreduction filtration system
Snyder EL, Whitley P, Kingsbury T, Miripol J, Tormey CA. In vitro and in vivo evaluation of a whole blood platelet‐sparing leukoreduction filtration system. Transfusion 2010, 50: 2145-2151. PMID: 20497514, DOI: 10.1111/j.1537-2995.2010.02701.x.Peer-Reviewed Original ResearchMeSH KeywordsBlood DonorsBlood PreservationErythrocytesHumansLeukocyte Reduction ProceduresLeukocytesPlasmaPlatelet TransfusionConceptsRed blood cellsWhite blood cellsAutologous plateletsTransfusion productsBlood cellsAdverse clinical sequelaeCPD plasmaProduction of plateletsResidual white blood cellsClinical sequelaeDrug Administration requirementsHospital useVivo efficacyLeukoreduction filtersBlood centersStudy designVivo evaluationLR productsVivo characteristicsPlateletsRBC recoveryAdministration requirementsVitroSurvival ratioFDA guidelines